Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma

Ben F J Goudsmit; Ilaria Prosepe; Maarten E Tushuizen; Vincenzo Mazzaferro; Ian P J Alwayn; Bart van Hoek; Andries E Braat; Hein Putter

doi:10.1016/j.jhepr.2023.100907

Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma

JHEP Rep. 2023 Sep 13;5(12):100907. doi: 10.1016/j.jhepr.2023.100907. eCollection 2023 Dec.

Authors

Ben F J Goudsmit¹, Ilaria Prosepe², Maarten E Tushuizen^{1

3}, Vincenzo Mazzaferro^{4

5}, Ian P J Alwayn^{3

6}, Bart van Hoek^{1

3}, Andries E Braat⁶, Hein Putter²

Affiliations

¹ Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
² Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
³ Transplant Center, Leiden University Medical Center, Leiden, The Netherlands.
⁴ Department of Oncology, University of Milan, Milan, Italy.
⁵ Hepatology and Liver Transplantation Unit, Department of Surgery, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milan, Italy.
⁶ Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

Background & aims: In the USA, inequal liver transplantation (LT) access exists between patients with and without hepatocellular carcinoma (HCC). Survival benefit considers survival without and with LT and could equalise LT access. We calculated bias-corrected LT survival benefit for patients with(out) HCC who underwent a transplant, based on longitudinal data in a recent United States cohort.

Methods: Adult LT candidates with(out) HCC between 2010 and 2019 were included. Waitlist survival over time was contrasted to post-transplant survival, to estimate 5-year survival benefit from the moment of LT. Waitlist survival was modelled with a bias-corrected Cox regression, and post-transplant survival was estimated through Cox proportional hazards regression.

Results: Mean HCC survival without LT was always lower than non-HCC waitlist survival. Below model for end-stage liver disease (sodium) (MELD(-Na)) 30, patients with HCC gained more life-years from LT than patients without HCC at the same MELD(-Na) score. Only patients without HCC below MELD(-Na) 9 had negative benefit. Most patients with HCC underwent a transplant below MELD(-Na) 14, and most patients without HCC underwent a transplant above MELD(-Na) 26. Liver function [MELD(-Na), albumin] was the main predictor of 5-year benefit. Therefore, during 5 years, most patients with HCC gained 0.12 to 1.96 years from LT, whereas most patients without HCC gained 2.48 to 3.45 years.

Conclusions: On an individual level, performing a transplant in patients with HCC resulted in survival benefit. However, on a population level, benefit was indirectly decreased, as patients without HCC were likely to gain more survival owing to decreased liver function. For patients who underwent a transplant, a constructed online calculator estimates 5-year survival benefit given specific patient characteristics. Survival benefit scores could serve to equalise LT access.

Impact and implications: Benefit is a comparison of the survival with and without liver transplantation, and it is important when deciding who should undergo a transplant. Liver function is most important when predicting possible benefit from transplantation. Patients with liver cancer die sooner on the waiting list than similar patients without liver cancer. However, patients with liver cancer more often have better liver function. Most patients without liver cancer derive more benefit from transplantation than patients with liver cancer.

Keywords: Hepatocellular carcinoma; Liver transplantation; Survival benefit.